AXSM
What one share of Axsome Therapeutics holds
Pharmaceutical Preparations
We are a fully integrated biopharmaceutical company focused on developing innovative medicines for people impacted by central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and developing differentiated products with a focus on novel mechanisms of action, that have the potential to transform patient outcomes.
Axsome Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $15.25 |
|---|---|
| Profit | −$3.76 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$1.41 |
| Cash and investments | $6.12 |
| Debt | $3.87 |
| Book value | $1.59 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$1.42 | $0.01 | −$1.12 | — | — |
| 2017 | — | −$1.27 | $0.00 | −$1.16 | — | — |
| 2018 | — | −$1.15 | $0.00 | −$1.12 | — | — |
| 2019 | — | −$2.01 | $0.00 | −$1.36 | — | $4.84 |
| 2020 | — | −$2.77 | $0.00 | −$2.11 | — | $3.04 |
| 2021 | — | −$3.47 | $0.01 | −$2.89 | — | $0.41 |
| 2022 | $0.00 | −$4.60 | $0.02 | −$2.88 | — | $2.52 |
| 2023 | $5.96 | −$5.27 | $0.01 | −$3.21 | — | $4.03 |
| 2024 | $8.05 | −$5.99 | $0.01 | −$2.69 | — | $1.17 |
| 2025 | $12.83 | −$3.68 | $0.01 | −$1.89 | — | $1.74 |